Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

7.50am: Banks hit by Moody's downgrades, Eli Lilly ups guidance US stocks are expected to open lower with banks under pressure after Moody's downgraded ratings for a number of small to mid-sized lenders and as weak trade data in China saw commodity prices fall. In pre-market trading, futures for the Dow Jones Industrial Average were 0.7% lower, while those for the S&P 500 fell 0.8%, and contracts for the Nasdaq 100 futures were down 0.9%.

Dow seen lower as Moody's hits banks but Eli Lilly set to fly

Eli Lilly and Co (NYSE:LLY) stock is seen higher ahead of Tuesday's open after reporting a strong, expectation-beating, second-quarter performance led by type-2 diabetes drug Mounjaro. Revenue for the quarter increased by 28% year-over-year, totalling US$8.3 billion, beating Wall Street forecasts for US$7.58 billion, with the company highlighting ‘volume-driven growth'.

Eli Lilly stock up in premarket as Mounjaro diabetes drug sales surge

Eli Lilly's stock has been on a tear, driven by positive trial results for its Alzheimer's drug and progress with its promising obesity drug pipeline.

Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%

Shares of Eli Lilly & Co. LLY, +1.02% shot up 9.0% into record territory in premarket trading Tuesday, after the drug giant reported second-quarter profit and revenue that climbed above expectations and provided a big boost its full-year outlook, as results were helped by the $579 million received from the sale of rights for Baqsimi. Net income jumped to $1.76 billion, or $1.95 a share, from $952.5 million, or $1.05 a share, in the year-ago period.

Eli Lilly stock shoots up into record territory after earnings beat, a big increase in the full-year outlook

Eli Lilly beat Wall Street estimates for second-quarter profit on Tuesday, buoyed by strong demand for its new diabetes drugs Mounjaro, ahead of a decision on the medicine's use as a weight-loss treatment.

Eli Lilly beats profit estimates on strength of new diabetes drug

Revenue in Q2 2023 increased 28% as a result of volume-driven growth from Mounjaro, Verzenio, Jardiance and Taltz, as well as $579.0 million from the sale of rights for Baqsimi. Excluding revenue from Baqsimi, and COVID-19 antibodies in 2022, revenue in Q2 2023 increased 22%.

Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements

Nektar Therapeutics

Nektar Therapeutics on Monday sued Eli Lilly , accusing the drugmaker of undermining the prospects for Rezpeg, which Nektar was developing as a treatment for various autoimmune diseases.

Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment

Eli Lilly and Company is slated to unveil its second-quarter 2023 results on Tuesday (August), prior to the market opening, with Wall Street expecting earnings of $1.98 a share. That's up around 9% on the same period last year, and 15% ahead of the first quarter.

Eli Lilly expected to deliver a solid if unspectacular earnings update

Nektar Therapeutics (NASDAQ:NKTR) shares rallied more than 15% in Monday pre-market trading after the company released new efficacy data from phase 1b studies from rezpegaldesleukin (rezpeg) after the data were previously incorrectly calculated by Eli Lilly.  The new and corrected data highlight the important potential of REZPEG to help patients battling atopic AtD, a chronic skin condition that afflicts nearly 10% of Americans, Nektar said in a statement.

Nektar rallies after releasing new data for rezpeg after Eli Lilly got it wrong

Nektar Therapeutics' stock NKTR, +3.14% jumped 12.7% in premarket trade Monday, after the company said that efficacy data previously generated by its former partner Eli Lilly & Co. LLY, +0.07% for its atopic dermatitis treatment rezpegaldesleukin and presented at the Sept. 22922 EADV Congress were incorrectly calculated.

Nektar Therapeutics' stock jumps premarket after it says data presented by Eli Lilly for a skin treatment was incorrectly calculated

Vertex Pharmaceuticals

Vertex's business should get a major boost in the coming years with new approvals. Eli Lilly's expanding portfolio of new products will help it maintain its recent momentum.

2 Top Biotech Stocks to Buy in August

Eli Lilly & Co. LLY, -1.17% said Friday a late-stage trial of a treatment for a type of non-small cell lung cancer met its main goal. The Phase 3 trial dubbed Libretto-431 showed a statistically significant and clinically meaningful improvement in progression-free survival for Retevmo versus platinum-based chemotherapy in treating adults with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer.

Eli Lilly reports positive results in trial of tretment for non-small cell lung cancer

INDIANAPOLIS , Aug. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed – with or without pembrolizumab – as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC). The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS).

Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung 

Eli Lilly's current portfolio looks competitive when excluding its covid products. The company's pipeline of potential products is highly promising, too.

Beat the Dow Jones With This Unstoppable Dividend Stock

Biogen

Biogen and Eli Lilly are two major competitors in the field of Alzheimer's disease. Eli Lilly's medicine appears to slow the rate of cognitive decline more than Biogen's.

Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen

Marvell Technology

Carnival

TransDigm

United Rentals

Top AI stock Marvell Technology and Eli Lilly lead this weekend's watch list of five stocks near buy points as the new S&P 500 bull market revs back up.

AI Stock Marvell And Eli Lilly Lead 5 Names Near Buy Points As S&P 500 Rallies On

Mounjaro may rake in $25B of annualized sales by 2026, exceeding ABBV's Humira. This naturally explains Mr. Market's optimism surrounding the LLY's stock thus far. The same has been witnessed with NVO, with accelerating annualized obesity related revenues of $4.64B by the latest quarter, well exceeding its long-term goal of $3.72B by 2025. However, with a P/E of 49.69x, against the pharmaceutical peers' median at 14.40x and NVO's at 30.38x, we believe LLY's valuations are over-stretched, reminiscent of a ticking time bomb.

Eli Lilly: There Is No Logic To This Over Optimism

Eli Lilly said that two Phase 3 trials of its weight-loss drug tirzepatide showed patients lost 26.6% of their body weight on average, more than competitors.

Eli Lilly Says Weight-Loss Drug Helps Patients Lose 26% of Their Weight, More Than Rivals

The data bolsters Eli Lilly's position in the budding weight loss drug market and establishes the company as a formidable competitor to Novo Nordisk.

Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials

Danaher

Intuitive Surgical

Johnson & Johnson

McKesson

Teladoc

UnitedHealth Group

Healthcare continues to be a major industry and economic driver around the world. According to the American Medical Association, spending on healthcare in the U.S. totals more than $4 trillion each year, which works out to nearly $13,000 per person.

7 Millionaire-Maker Healthcare Stocks to Buy Before the Window Closes

Novo Nordisk

Eli Lilly has a couple of promising weight-loss treatments that could gain approval in the near future. Novo Nordisk's obesity care revenue doubled in the first quarter -- and stands to go still higher.

Eli Lilly vs. Novo Nordisk: What's the Better Weight-Loss Stock to Buy?

Eli Lilly said on Thursday its experimental weight-loss drug met the main goals in two late-stage studies.

Eli Lilly's obesity drug succeeds in two late-stage studies

Participants in SURMOUNT-3, after 12 weeks of intensive lifestyle intervention, achieved an additional 21.1% mean weight loss with tirzepatide for a total mean weight loss of 26.6% from study entry over 84 weeks Participants in SURMOUNT-4 achieved 21.1% weight loss during a 36-week tirzepatide lead-in period and an additional 6.7% weight loss during a 52-week continued treatment period, for a total mean weight loss of 26.0% over 88 weeks INDIANAPOLIS , July 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results of two phase 3 tirzepatide studies in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. SURMOUNT-3 and SURMOUNT-4 met all primary and key secondary objectives for tirzepatide compared to placebo.

Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies

C3.ai

Palantir Technologies

It's no secret that a few names have reached excessive valuations during the recent growth stocks rally. And so, they are overdue for a correction.

3 Risky Stocks to Avoid at All Costs in 2023

Eli Lilly has been a top performer over the past three years. Future appreciation will depend on how the competitive landscape in weight loss evolves.

News for Eli Lilly Stock (LLY)